Applied Sciences | |
Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis | |
PatrickImesch1  Julian MatthiasMetzler2  Daniel Fink3  | |
[1] Department of Gynecology, University Hospital Zurich, Frauenklinikstrase 10, 8091 Zurich, Switzerland;Department of Gynecology, University Hospital Zurich, Frauenklinikstrasse 10, 8091 Zurich, Switzerland;Faculty of Medicine, University of Zurich, Pestalozzistrasse 3/5, 8091 Zurich, Switzerland; | |
关键词: ibrutinib; Bruton’s tyrosine kinase; Btk; kinase inhibitor; ovarian cancer; gynecological oncology; | |
DOI : 10.3390/app11010222 | |
来源: DOAJ |
【 摘 要 】
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase, an enzyme central in B cell development. It is indicated as a therapy for certain hematological diseases such as chronic lymphocytic leukemia (CLL), but also exerts off-target effects on several receptors and kinases. In this paper, we hypothesize that ibrutinib may suppress the tumor marker CA-125 in ovarian cancer. The hypothesis is based on an observation of CA-125 normalization in a patient with low-grade serous ovarian cancer who received ibrutinib for concurrent CLL. We propose a mechanistic model explaining this possible drug effect as a foundation for further research.
【 授权许可】
Unknown